NCT06182592 2023-12-28A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid LeukemiaCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Phase 3 Not yet recruiting120 enrolled